Advanced Search

Study Preview



Study Title and Description

A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults.
Author Vulevic J., Juric A., Tzortzis G., Gibson GR.
Country Department of Food and Nutritional Sciences, Food Microbial Sciences, and.
Year 2013
Numbers Pubmed ID: 23303873

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 2013
  • Comments Comments (
    0
    ) |
Country of Publication United Kingdom
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
Was the study blinded? double blind
  • Comments Comments (
    0
    ) |
Study diet type Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 48
  • Comments Comments (
    0
    ) |
Is there a run-in period? Unspecified
  • Comments Comments (
    0
    ) |
Is there a washout period? Yes
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years ~44.6
  • Comments Comments (
    0
    ) |
Study population, age range in years -
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 ~31.4
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 -
  • Comments Comments (
    0
    ) |
Baseline health status overweight, with 3 or more markers of metabolic syndrome
  • Comments Comments (
    0
    ) |
Gender (% male) 36
  • Comments Comments (
    0
    ) |
Fiber 1-type Galactooligosaccharide
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) 5.5
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 12 weeks
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Powder
  • Comments Comments (
    0
    ) |
Fiber 2-type -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 3-type -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 4-type -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? placebo
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 12 weeks
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Powder
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.